FACTOR THERAPEUTICS LIMITED (FTT)

name changed to Dominion Minerals Limited

Drilling program has commenced at Dominion's high calcium lime project in Georgia, USA. Previous exploration work undertaken by PowerLime included drilling 8 sonic holes and 8 test pits, which identified limestone intersections of up to 10m from near surface. â–ª Dominion's drilling program will comprise ~12 drill holes across the project, building upon the work undertaken by PowerLime. The drilling program will be overseen by a team of U.S. based specialists in mineral exploration with significant experience in the south-east of the USA. Results of the drilling program will be released to the market as they become available, and are expected to be incorporated into a future mineral resource estimate at the project.

The company lodges its Appendix 4C and Activities Report - September 2021 quarter.

The company releases a notice of application for quotation of securities.

The company's public offer to raise $4M through the issue of 100,000,000 shares at an offer price of $0.04 is complete.

The company releases an application for quotation of securities.

The company releases a notification regarding unquoted securities..

Further to Shareholder approvals received at the Company's Extraordinary General Meeting held on 9 September 2021, Dominion Minerals Limited is pleased to confirm that it has completed the acquisition of PowerLime, Inc. The Company is seeking to raise $4M through the issue of 100,000,000 shares at an offer price of $0.04 from existing and new Shareholders. The Offer, which is being conducted under a Prospectus, closes on Friday 1 October 2021.

The company releases a notice of roposed issue of securities.

The company provides an update on the consolidation of its securities.

The company releases the results of its meeting.

The company releases its Chairmans Address to EGM.

The company releases a replacement prospectus which replaces the prospectus dated 27 August 2021.

The company releases a prospectus for the offer of 100,000,000 shares at a price of $0.04 per share to raise $4,000,000. The offer comprises: a priority offer to eligible shareholders of the company as at the record date; and an offer to the general public. The offer is scheduled to cloase at 5.00pm (AEST) on 1 October 2021 unless extended or withdrawn.

The company releases a notification of consolidation of its securities. Shareholders get 1 share for every 10 presently owned.

The company will hold an Extraordinary General Meeting on 9 September 2021 commencing at 1:00pm (AEST). Shareholders and proxyholders will be able to participate in the EGM by accessing https://agmlive.link/agm/FTTEGM21/register.

The company lodges its Appendix 4D and Financial Report for half year to 30 June 21.

Factor has now entered into a conditional Share Purchase Agreement with PowerLime and the PowerLime shareholders, to acquire all issued shares in PowerLime. The Transaction will result in a significant change in the nature and scale of the Company's activities, away from life sciences and into the resources sector. Shareholder approval of this significant change will be required. The SPA is conditional upon the Company obtaining such approval. Following financial close of the Transaction, the Company will seek reinstatement to official quotation of the Company's shares on the ASX and will undertake a A$4M capital raise at an offer price of A$0.004. The Company is preparing a Notice of Extraordinary General Meeting and Explanatory Memorandum which sets out the Shareholder Resolutions necessary to complete the Transaction, seek Official Quotation on ASX and undertake the Offer.

The company lodges its App 4C and Activities Report including transaction status.

The company releases a notification of cessation of securities.

The company releases its Results of Meeting.

The company releases its Chairman's Address to AGM and Presentation on PowerLime Inc.

The company lodges its Appendix 4C and Activities Report - March 2021 quarter.

The company releases a notice of meeting and explanatory memorandum. The AGM is due to be held on 28 May 2021 commencing at 1:00pm (AEST). Virtual meeting link: https://agmlive.link/FTT21.

The company has entered into a term sheet with PowerLime for the acquisition of PowerLime and its assets. The acquisition is proposed to be implemented by means of a purchase agreement. The result will be that PowerLime becomes a wholly owned subsidiary of Factor, with the goal of pivoting Factor into a resources company.

The company releases its Corporate Governance Statement.

The company releases an App 4G - Key to Governance Disclosures.

The company lodges its App 4E and Annual Report for year ended 31 December 2020.

The company has appointed Taylor Collison Limited as corporate advisor to assist the Board in broadening the focus and access of commercial opportunities, particularly in areas beyond the current Board's specific expertise in biotechnology.

The company lodges an Appendix 4C and Activities Report - December 2020 Quarter.

For shareholders wishing to attend the shareholder briefing call scheduled for 8.00am (AEDT) on Wednesday 20 January 2021, they can register at https://s1.c-conf.com/DiamondPass/10011888-9j75fa.html.

By mutual agreement, FTT and LONGMILE agreed to two extensions of the exclusivity agreement while the Company awaited ASX feedback on the in principle advice application. To date, the Company has still not received any definitive in-principle ASX advice regarding the transaction. Due to the considerable prolongation of the transaction and changes in business circumstances in the interim, the parties have not been able to finalise acceptable commercial terms. As a result the parties have elected by mutual agreement to cease negotiation, with no further penalty. A shareholder briefing call is scheduled for 8.00am (AEDT) on Wednesday 20 January 2021.

ASX has provided notice that a decision on the Company's application for in-principle advice is anticipated to be received early in 2021. By mutual agreement the exclusivity agreement in place between the parties is extended to accommodate the current status.

Factor Therapeutics and Brain Biosciences executed a non-binding term sheet for the potential transaction. This included a 120-day exclusivity, "no shop" and "no talk" period for the parties to use commercially reasonable efforts to complete due diligencce and conclude the negotiation of formal transaction documents for the acquisition of the exclusive, global rights to LONGMILE's veterinary product portfolio. The exclusivity agreement has been extended until 31 December 2020.

The company lodges its App 4C and Activities Report September 2020 Quarter.

The company releases the Results of its Meeting.

The company releases its Chair Address to AGM and LONGMILE presentation.

The company lodges its Appendix 4D and Report for half-year to 30 June 2020.

The company will remain suspended following the announcement that it has entered into a term sheet relating to the negotiation and potential implementation of a transaction to acquire certain technologies from Brain Biosciences. FTT's securities will remain suspended until ASX is satisfied that all relevant information required under Guidance Note 12: Change to Activities has been announced. If the Acquisition proceeds, ASX is likely to exercise its discretions under Listing Rule 11.1.2 to require the Acquisition to be conditional on approval by FTT's ordinary security holders and under Listing Rule 11.1.3 to require FTT to recomply with Chapters 1 and 2 of the Listing Rules.

The company has entered into a term sheet with Rockville-based Brain Biosciences, Inc. doing business as LONGMILE Veterinary PET Imaging, a commercial-stage veterinary medical technology company, relating to the negotiation and potential implementation of a transaction to acquire products and technologies for companion animal and equine veterinary imaging from LONGMILE.

The company lodges its Appendix 4C and Activities Report - June 2020 Quarter.

The securities of Factor Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of FTT, pending the release of an announcement regarding details of a proposed acquisition.

name changed from Tissue Therapies Limited